- Home
- SRG
as 07-26-2024 4:00pm EST
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 262.8M | IPO Year: | 2015 |
| Target Price: | N/A | AVG Volume (30 days): | 370.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.37 - $9.87 | Next Earning Date: | 08-12-2024 |
| Revenue: | $25,873,000 | Revenue Growth: | -66.32% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Seritage Growth Properties News
SRG Breaking Stock News: Dive into SRG Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Investors in Seritage Growth Properties (NYSE:SRG) have unfortunately lost 89% over the last five years
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
2 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
AFP
2 months ago
New Zealand scraps plan to tax livestock burps, farts
The Wall Street Journal
2 months ago
ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
Business Wire
2 months ago
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
Bloomberg
2 months ago
UK Unemployment Rises in Sign Inflationary Pressures Cool
Compare SRG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRG Seritage Growth Properties - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.